Article

Evaluating the economic impact of eculizumab biosimilars in Germany

2026-04-15

Abstract excerpt

<title>Abstract</title> <p>Background Eculizumab, a humanized monoclonal antibody, inhibits activation of complement component C5. For patients with atypical hemolytic uremic syndrome, the introduction of eculizumab has markedly improved survival, restoring life expectancy close to that of the general population. The long-acting C5 complement inhibitor (CI) ravulizumab has since expanded treatment options, offer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f5f9eef7-18dd-5220-a572-acfb38180072
DOI: 10.21203/rs.3.rs-9140376/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluating the economic impact of eculizumab biosimilars in GermanyDOI 10.21203/rs.3.rs-9140376/v1Read

The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity Read

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read

Biologic therapies for lupus nephritis: a systematic review of efficacy, safety, and cost-effectivenessSemantic proximity Read

Treatment discontinuation in atypical hemolytic uremic syndrome (aHUS): A qualitative study of international experts’ perspectives with associated cost-consequence analysisSemantic proximity Read

Comparative real-world retention rate and safety of Biosimilar IBI303 versus Humira in Ankylosing SpondylitisSemantic proximity Read

Applying the Efficiency Frontier to Inform Value-Based Pricing for Gaucher Disease Therapies in BrazilSemantic proximity Read

Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).Semantic proximity Read

Cost-effectiveness of anti-CD20 monoclonal antibody associated with fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia in the Brazilian public health system (SUS)Semantic proximity Read

The impact of eculizumab on routine complement assaysSemantic proximity Read

Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness AnalysisSemantic proximity Read

Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?Semantic proximity Read

Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?Semantic proximity Read